Clinical assessment and cytokines level in constipation-predominant irritable bowel syndrome participants treated with Lactobacillus-containing cultured milk drink

• Main Authors: Abdul Rani, R. (Author), Alfian, E. (Author), Jaafar, N.Md (Author), Mohd Rathi, N.D (Author), Mokhtar, N.M (Author), Raja Ali, R.A (Author)
• Format: Article
• Language: English
• Published: Universa Press 2021
• Series: Acta Gastro-Enterologica Belgica
• Subjects: Cultured milk products; IL-6; IL-8; Irritable bowel syndrome; TNF-alpha
• Online Access: View Fulltext in Publisher; View in Scopus
• ISBN: 17843227 (ISSN)
• DOI: 10.51821/84.4.009

Background: Gut dysbiosis is linked with the pathophysiology of irritable bowel syndrome (IBS). Manipulation of intestinal microbiota using cultured milk drinks may stimulate the immune system, hence providing beneficial support in IBS treatment. This study aimed to investigate the effects of cultured milk drink on clinical symptoms, intestinal transit time (ITT), fecal pH and cytokines in constipation-predominant IBS (IBS-C) as compared to non-IBS participants. Methods: Each recruited participant was given three bottles of 125 ml cultured milk drink containing 109 cfu Lactobacillus acidophilus LA-5 and Lactobacillus paracasei L. CASEI-01 consumed daily for 30 days. At pre-and post-30-day consumption, fecal pH, ITT, clinical symptoms, IL-6, IL-8 and TNF-α levels were assessed. Seventy-seven IBS-C and 88 non-IBS were enrolled. Results: Post-consumption, 97.4% of IBS-C experienced improvements in constipation-related symptoms supported by the significant reduction of ITT and decreased fecal pH (p<0.05). All pro-inflammatory cytokines were significantly lower in post as compared to pre-consumption of cultured milk drinks in IBS-C (p<0.05). There was significant reduction in the IL-8 and TNF-α levels in post-as compared to pre-consumption for the non-IBS (p < 0.05). Conclusion: Cultured milk drink taken daily improved clinical symptoms and reduced cytokines, hence should be considered as an adjunctive treatment in IBS-C individuals. © 2021, Universa Press. All rights reserved.